Experience

We secured a favorable resolution of all claims on behalf of Signify

The debut offering consisted of 2.143% senior notes due 2026

We secured a total victory for the clients, with all claims against them dismissed

We are serving as lead trial counsel for Magnolia Medical in an action against its sole competitor

We are defending Signify Health against trade-secret-misappropriation and related claims

Davis Polk advised Coloplast on its acquisition of Nine Continents Medical, an early stage company pioneering an implantable tibial nerve stimulation treatment for over-active bladder. The…

Davis Polk is advising Gilead Sciences, Inc. in its acquisition of Immunomedics, Inc. for $88.00 per share in cash. The transaction, which values Immunomedics at approximately $21 billion,…

Davis Polk is advising Bristol Myers Squibb on its acquisition of Forbius. The transaction includes an upfront payment and future success-based milestone payments. The transaction is…

Davis Polk is advising J M Smith Corporation in connection with the sale of its technologies division, Smith Technologies, to private equity sponsor Francisco Partners, pursuant to a…

Davis Polk is advising Nutrisystem, Inc. on its $1.4 billion acquisition by Tivity Health, Inc. The transaction, which is expected to close in the first quarter of 2019, is subject to…